Skip to main content

Cepheid Shares Slide 7.3 Percent on Wider Q4 Net Loss and Predictions of More Red in 06

NEW YORK, Feb. 23 (GenomeWeb News) - Cepheid shares were down 7.31 percent, or $.71, at $9 in afternoon trade after the company reported a wider fourth-quarter net loss and forecast deeper losses in 2006.

 

Cepheid yesterday reported a a net loss of $3.2 million, or $.08 per share during the third quarter, compared with a net loss of $3.0 million, or $.07 per share during the same quarter last year.

 

The company said fourth quarter revenues rose 16 percent to $23.6 million from $20.3 million year over year, driven by 15 percent growth in product sales.

 

The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables, which increased to $22.2 million from $19.4 million in the year-ago period.

 

R&D spending during the quarter rose to $5.2 million, compared to $4.4 million during the fourth quarter last year.

 

Cepheid expects a net loss in the range of $7 million to $9 million in 2006 on product sales in the range of $94 million to $98 million.

 

As of Sept. 30, 2005, Cepheid had $16.1 million in cash and cash equivalents and $21.2 million in marketable securities.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.